Exhibit 99.1 INEEX For Immediate Release BioLineRx Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motixafortide plus G-CSF versus plerixafor plus G-CSF - - Cash and cash equivalents at December 31, 2021 of $57 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 19 ...

Financial Data and Key Metrics Changes - Research and development expenses for the nine months ended September 30, 2021, were $14.3 million, an increase of $0.8 million or 5.9% compared to $13.5 million for the comparable period in 2020 [34] - The company held $62.2 million in cash, cash equivalents, and short-term bank deposits as of September 30, 2021, indicating strong financial positioning to achieve multiple value-creating milestones [35] Business Line Data and Key Metrics Changes - The GENESIS Phase 3 study reported that 89% of patients receiving Motixafortide in combination with G-CSF mobilized the optimal number of cells after only one administration and one apheresis session, compared to 10% for G-CSF alone [10][12] - The median number of cells collected in one apheresis session was 11 million for the Motixafortide G-CSF arm, significantly higher than the 2 million cells collected with G-CSF alone [11][22] Market Data and Key Metrics Changes - The global estimated market for autologous stem cell transplantation is approximately $500 million, with over 45,000 procedures performed annually in the U.S. and Europe [24] - The first-generation CXCR4 inhibitor, plerixafor, generates annual sales exceeding $250 million, primarily used as a rescue therapy [24] Company Strategy and Development Direction - The company plans to submit a New Drug Application (NDA) to the FDA in the first half of 2022, following a pre-NDA meeting scheduled for mid-December [25][37] - Future plans include evaluating lifecycle management potential in other autologous stem cell mobilization indications and exploring partnerships for commercialization rather than self-commercialization [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the positive results from the GENESIS study and the pharmacoeconomic study, viewing them as significant milestones for the company [38][56] - The company anticipates a catalyst-rich 2022, with meaningful clinical benefits for patients and considerable value creation for shareholders [56][57] Other Important Information - The pharmacoeconomic study indicated a net cost savings of approximately $17,000 per patient when using Motixafortide in combination with G-CSF compared to the current standard-of-care [20][21] - The company has a notable presence at the upcoming American Society of Hematology Annual Meeting, with four abstracts accepted for presentation [29][30] Q&A Session Summary Question: Key components for the upcoming pre-NDA meeting with the FDA - Management aims to align with the FDA on the overall content of the NDA submission [40][41] Question: Next steps for AGI-134 and potential randomized studies - Future steps will depend on the data from the current study, with considerations for patient populations and combination therapies [42][44] Question: Update on the timing of the first data for the academic sponsored trial - Recruitment is ongoing for the investigator-initiated trial, but specific timelines cannot be provided [46][47] Question: Delay in AGI-134 data and presentation at conferences - Recruitment delays were primarily due to COVID-19, but completion is expected by the end of the year, with data anticipated in the first half of next year [48][49] Question: Commercialization strategy for Motixafortide - The company is exploring collaboration options for commercialization rather than self-commercialization due to operational and financial risks [52] Question: Applicability of pharmacoeconomic study results in Europe - The cost structure in Europe differs from the U.S., and while the model can be adapted, the company believes similar significant benefits could be observed [54]

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2021 Earnings Conference Call August 18, 2021 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein-Haras - Chief Medical Officer Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2021 Results Con ...

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2021 Earnings Conference Call May 26, 2021 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Avi Vainstein - Chief Medical Officer Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2021 Results Conference Ca ...

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2020 Earnings Conference Call February 23, 2021 10:00 AM ET Company Participants Timothy McCarthy - LifeSci Advisors Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Avi Vainstein - Chief Medical Officer Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLine Rx Fourth Quarter and Full Year 2020 Results Conference Call. All par ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 19 ...

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2020 Earnings Conference Call November 23, 2020 10:00 AM ET Company Participants Timothy McCarthy - IR, LifeSci Advisors, LLC Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President-Clinical Development Conference Call Participants Joe Pantginis - HC Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2020 Results Conference Call. All partic ...

BioLine RX Ltd (NASDAQ:BLRX) Q2 2020 Earnings Conference Call August 6, 2020 10:00 AM ET Company Participants Timothy McCarthy - LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical Development Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2020 Results Conference Call. [Operator Instructions]. I would now like to turn the call ...

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2020 Earnings Conference Call May 20, 2020 10:00 AM ET Company Participants Timothy McCarthy - Investor Relations, LifeSci Advisors Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President, Clinical Development Ella Sorani - Vice President, Research and Development Conference Call Participants Joe Pantginis - H.C. Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the ...